In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin
about
sameAs
Antituberculosis therapy for 2012 and beyondAntimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophagesIn vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosisAntimycobacterial activities of novel levofloxacin analoguesComparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosisIn vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosisActivities of various quinolone antibiotics against Mycobacterium leprae in infected mice.Clinical trial of sparfloxacin for lepromatous leprosy.Fluoroquinolones and tuberculosis.Tuberculosis chemotherapy: current drug delivery approaches.Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients.Recent developments in the treatment of tuberculosis.Levofloxacin and sparfloxacin: new quinolone antibiotics.Intracellular accumulation of norfloxacin in Mycobacterium smegmatisEffect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria.Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms.Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis.Ciprofloxacin once daily versus twice daily for the treatment of pulmonary tuberculosis.
P2860
Q26829101-780C1399-18E5-4E90-A25E-AB5064946640Q28322331-D1D14116-DF47-449E-9FFD-3D464F30ED19Q28327072-188E2F2C-46B2-4901-8E2A-C0332492E41EQ28344486-6E33AA11-C5AD-43C1-8BD2-94D23F1BF5F9Q28368212-85EE862B-0874-47F4-A9DA-99081AA8B057Q28379137-60D88080-2582-4C31-8089-335930887E6AQ33746188-9CC6E00B-4B83-49E4-8CB4-E271CD1DEC4CQ33747177-A078D7D7-1725-4873-AEE0-3721736C88AFQ34519143-174F46F1-88AC-4B4F-82F9-7625E7A87D34Q35069271-5C0FEEA5-5AED-4D56-B150-CF2B00F7622DQ35116979-3E02A80D-2DFF-4549-B11D-4117023D931FQ35185753-2A555E6A-5E35-4F69-84E1-B7538992C154Q37881273-9E17474A-9814-4BCC-B0DB-12329261E313Q39780762-BA74B7FF-AB4F-439D-A57D-7C5A1BDF853DQ40088981-8498CD11-DE93-459C-805D-533D9E253BFFQ42285782-2410D56D-A97D-4E4D-A962-82992EE1208AQ44570155-1D988206-B728-49E0-A796-66B45B9EBE66Q44777989-0F05F554-E9AF-40CD-97E4-C95FDA5EE9A9
P2860
In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin
description
1991 nî lūn-bûn
@nan
1991 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
In vitro activity of the new d ...... of ofloxacin and ciprofloxacin
@ast
In vitro activity of the new d ...... of ofloxacin and ciprofloxacin
@en
In vitro activity of the new d ...... of ofloxacin and ciprofloxacin
@nl
type
label
In vitro activity of the new d ...... of ofloxacin and ciprofloxacin
@ast
In vitro activity of the new d ...... of ofloxacin and ciprofloxacin
@en
In vitro activity of the new d ...... of ofloxacin and ciprofloxacin
@nl
prefLabel
In vitro activity of the new d ...... of ofloxacin and ciprofloxacin
@ast
In vitro activity of the new d ...... of ofloxacin and ciprofloxacin
@en
In vitro activity of the new d ...... of ofloxacin and ciprofloxacin
@nl
P2860
P356
P1476
In vitro activity of the new d ...... of ofloxacin and ciprofloxacin
@en
P2093
P2860
P304
P356
10.1128/AAC.35.9.1933
P407
P577
1991-09-01T00:00:00Z